State Street (SNDX holder) discloses 5.3% Syndax Pharmaceuticals ownership stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
STATE STREET CORPORATION reported a significant ownership stake in Syndax Pharmaceuticals Inc. common stock. As of 12/31/2025, it beneficially owned 4,596,552 shares, representing 5.3% of the company’s common stock.
State Street reported no sole voting or dispositive power, but shared voting power over 4,341,322 shares and shared dispositive power over 4,596,552 shares. The position is certified as being held in the ordinary course of business and not for influencing control of Syndax.
Positive
- None.
Negative
- None.
FAQ
What ownership stake does State Street report in Syndax Pharmaceuticals (SNDX)?
State Street Corporation reports beneficial ownership of 4,596,552 shares of Syndax Pharmaceuticals common stock, representing 5.3% of the outstanding class as of December 31, 2025. This makes State Street a significant institutional holder of SNDX shares.
Is State Street’s Syndax (SNDX) stake intended to influence control?
State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Syndax. The holding is characterized as a passive institutional investment position.
Who is the reporting person for this 5.3% Syndax (SNDX) ownership?
The reporting person is State Street Corporation, organized in Massachusetts, with a principal office at One Congress Street, Suite 1, Boston, MA 02114. Several State Street Global Advisors entities are identified as relevant investment adviser subsidiaries.
What subsidiaries are associated with State Street’s SNDX holdings?
Associated entities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each identified as investment advisers involved with the reported holdings.